Clinical Trial Updates (SCD)

Ferriprox® (deferiprone)

Update: 30 September 2022

No update available.

 

Update: 30 June 2022

No update available.

 

Update: 25 April 2022

No update available

 

Update: 10 January 2022

No update available.

 

Update: 27 October 2021

  • Regulators in Brazil have approved Ferriprox (deferiprone) for people with sickle cell disease (SCD) or other anemias. The decision by Brazil’s National Health Surveillance Agency follows a similar label expansion in the U.S. — where the therapy was available for thalassemia patients when current iron-chelating medication was ineffective — to include adults and children, ages 3 and older, with SCD or other anemias.
  • Health Canada has expanded its approval of Ferriprox (deferiprone) to patients who have blood transfusion-induced iron overload due to sickle cell disease (SCD) or other anemias.

Sources: https://sicklecellanemianews.com/2021/10/19/health-canada-ferriprox-treat-iron-overload-sickle-cell-disease/
https://sicklecellanemianews.com/2021/09/16/ferriprox-approved-brazil-iron-overload-scd-other-anemias/

Check Also
Close
Back to top button